EGFR-IN-139
EGFR-IN-139 (compound PD 18) is an epidermal growth factor receptor (EGFR) inhibitor, with IC50s of 12.88 (wild type), 10.84 (L858R/T790M), 42.68 (L858R/T790M/C797S) nM, respectively. EGFR-IN-139 displays strong anticancer activity against A549 and H1975 cancer cell lines, which are highly expressed EGFR. EGFR-IN-139 has a strong selectivity to cancer cells. EGFR-IN-139 can be used for nonsmall cell lung cancer (NSCLC) research[1].
Product Specifications
CAS Number
[1574321-31-5]
UNSPSC
12352005
Target
EGFR
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Smiles
O=C(C1=CC=C2OCCOC2=C1)C(O3)=CC4=C3C(C)=NC=C4CN5CC6=C(C=CC=C6)CC5.Cl
Molecular Formula
C27H25ClN2O4
Molecular Weight
476.95
References & Citations
[1]Todsaporn D, et al. Furopyridine Derivatives as Potent Inhibitors of the Wild Type, L858R/T790M, and L858R/T790M/C797S EGFR. J Phys Chem B. 2024 Dec 19;128 (50) :12389-12402.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
